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1. Introduction  
Degenerative spinal disorders including low back pain are one of the most common and 
costly problems for modern society. It has been recognized that these disorders are directly 
or indirectly associated with intervertebral disc degeneration. The disc is a cartilaginous 
connective tissue, composed of the nucleus pulposus(NP), annulus fibrosus and endplates, 
which connects adjacent vertebrae (the functional spinal unit) and plays major roles in 
promoting the flexibility and stability of the lumbar spine. The NP is comprised of 
chondrocytic cells (nucleus pulposus cells) in an extensive extra-cellular matrix such as 
proteoglycan or collagen. Large molecules of proteoglycan exist in collagen networks and 
the high osmotic pressure produced by proteoglycan can result in inbibing water into the 
encapsulated NP, leading to high positive pressure inside the disc (Nachemson et al., 1970). 
The maintainance of this high positive presure inside of the disc is important in ensuring the 
biomechanical strength of the disc (Figure 1). 
 
 
Fig. 1. Functional spinal unit and the biomechanical stability of the normal disc. 
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In the process of disc degeneration, the loss of an important extra-cellular matrix such as 
proteoglycan leading to loss of water from the nucleus pulposus, results in loss of the 
biomechenical stability of the disc. In this process, since the capability for regeneration of the 
degenerated disc is very limited, clinical treatment of degenerative disc disorders, especially 
if there is mechanical instability in this segment, often necessitates removal of the 
degenerated disc and fusion of this segment (spinal fusion) with or without metal 
instruments (Figure 2). Spinal fusion has been one of the main surgical treatments for 
degenerative disc disorders with acceptable clinical results. However, there are several 
problems associated with spinal fusion surgery, such as accerelated degeneration in the disc 
adjacent to the fused segnment (Lee, 1988), breakage of instruments and damage to the 
nerve tissue during the instumentation procedure (West et al., 1991). In addition, the 
procedure is highly invasive, costly, and the risc of infection is comparatively high.  
 
 
Fig. 2. Theoretical disc degeneration process (Kirkaldy & Farfan, 1982). 
To overcome these problems attention has recently turned to biological treatment methods 
in an effort to stimulate the regeneration process of the degenerated discs. Due to the 
relatively well encapsulated and avascular enviroment of the disc, it seems preferable to 
deliver bioactive materials into the disc to obtain positive biological effects which can 
maintain or regenearate disc tissue. Biological treatment for the degenerated disc can be 
divided into three major categories: 1) growth factor injection with or without a carrier, 2) 
cell transplantation including stem cells, and 3) gene therapy. However, it is clear that the 
disc has unique anatomical and physiological properties, which challenge many traditional 
biological approaches. Therefore, we discuss the possiblity of biological treatment 
approaches especially from the view point of delivery of molecular materials to the disc. 
One of the most significant advantages of gene therapy may be the sustained biological 
effect making it potentially suitable in the treatment of chronic diseases such as spinal 
disorders, particularly those disorders associated with disc degeneration.   
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2. Intradiscal gene therapy  
2.1 Previously reported intradiscal gene therapy  
In vitro gene therapy approaches for the disc were first reported in 1997 and in vivo 
approaches in 1998. Attempts at intradiscal gene therapy using viral vectors have been 
made; however, due to the potential risks associated with viral gene therapy, the non-virus 
mediated intradiscal gene transfer method has been developed (see later discussion). 
2.1.1 Virus vector-mediated intradiscal gene therapy 
In 1997, Wehling et al. reported gene transfer to the chondrocytic cells from bovine 
intervertebral endplates using retrovirus vector in vitro (Wehling et al., 1997). This was the 
first report of gene therapy targeting the disc in vitro, and the authors indicated the potential 
use of indirect, ex vivo gene therapy for the degenerated disc by re-injecting genetically 
modified chondrocytic end-plate cells into the disc or surrounding tissue. 
In 1998, Nishida and Kang et al. reported intradiscal direct gene transfer to the disc using an 
adenoviral vector in vivo with a rabbit model. This report was recognised as the first gene 
therapy approach targeting nucleus pulposus cells in vitro and in vivo. In their report, 
reporter gene expression continued in vivo at a seemingly undiminished level for at least 12 
weeks. Later, their follow-up report using two different reporter genes showed the 
longevity of the transgene expression extended over 1 year. The results of these reports 
suggested that the adenoviral vector might be suitable for delivery of therapeutic genes to 
the disc, using an in vivo, direct gene therapy approach for the treatment of spinal disorders.  
In their next study, Nishida and Kang et al. reported an in vivo study using the rabbit model 
once again to determine the feasibility of the adenovirus-mediated transfer of a therapeutic 
gene to the intervertebral disc. They used an adenovirus construct containing a human 
transforming growth factor-beta1 (TGF-beta1) encoding gene (Ad/CMV-TGF beta1). In vivo 
injection of Ad/CMV-TGF beta 1 into the normal nucleus pulposus was revealed to result in 
an approximately six-fold increase in total (i.e., active + latent) TGF- beta 1 production over 
that of the intact control discs. The discs of the therapeutic gene group exhibited a 
statistically significant two-fold increase in proteoglycan synthesis compared to the intact 
control discs. This study demonstrated the efficacy of adenovirus-mediated transfer of a 
therapeutic gene to the intervertebral disc in vivo. The observation of a significant increase in 
proteoglycan synthesis secondary to gene transfer suggested that gene therapy might have 
potential applications in changing the time-course of degenerative disc disease. 
Recently, Liang et al. reported the successful curative effects of gene therapy for the 
treatment of the degenerated disc in a novel mice model by adenoviral mediation of the 
human growth and differentiation factor-5 (GDF-5) gene (Liang et al., 2010). Their study 
confirmed the long-term expression of the target protein in the disc in vivo and also 
demonstrated the physiological improvements occurring in the disc. 
Meanwhile, Lattermann et al. reported adeno-associated virus (AAV) vector-mediated gene 
transfer to intervertebral disc in vivo (Lattermann et al., 2005). AAV vectors are understood 
to be less immunogenic than adenoviral vectors and as yet have not been linked with any 
disease in humans or mammals. The overall transgene expression was approximately half of 
that seen with the adenovirus, and the in vivo gene expression was associated with a 4–6 
week latency period. They concluded that due to safety concerns over the use of adenoviral 
vectors for human gene therapy, the AAV vector might offer a valuable alternative to the 
adenovirus as a delivery vehicle for therapeutic gene transfer into the intervertebral disc. 
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Liu et al. reported the usefulness of baculovirus for the disc (Liu et al., 2006). Baculovirus is 
an insect virus able to deliver exogenous genes to mammalian cells including nondividing 
cells with no cell toxicity in vitro or in vivo. They concluded that baculovirus could transfer 
exogenous genes into rabbit nucleus pulposus cells safely and with high efficiency both in 
vitro and in vivo. 
2.1.1 Nonvirus vector-mediated intradiscal gene therapy 
Although the development of more sophisticated viral vectors such as non-toxic and safer 
vectors is still being investigated, progress in intradiscal gene therapy has been delayed by 
worries over the safety and potential costs of using recombinant viral vectors. Therefore, a 
number of non-virus mediated gene transfer techniques have been developed. However, the 
lower transfection efficiency compared with viral vector-mediated methods has been a 
major limitations of the non-virus mediated method, making the in vivo, direct gene transfer 
approach infeasible.  
In 2006, Nishida et al. reported the efficacy of so-called “microbubble-enhanced ultrasound 
gene therapy” to the disc. More recent evidence suggested an appropriate intensity of 
ultrasound exposure could make a small transient hole on the cell membrane in a 
phenomenon called sonoporation, without causing cell toxicity. Additionally, it was 
reported that a kind of ultrasonography contrast agent called “micro-bubble” makes a 
cavitation with the exposure of ultrasound and this results in the bursting of the 
microbubbles leading to a distribution of material over a specific area of interest. Both these 
phenomenon, sonoporation and cavitation, are thought to have synergistic effects for 
increased transfection efficiency (Lawrie et al., 1999, 2000).  
They demonstrated this micro-bubble enhanced ultrasound gene therapy in the 
intervertebral disc in vivo using a rat model. In their study, two different reporter plasmid 
DNA were used. They discovered that the ultrasound group demonstrated approximately 
an 11-fold increase in transgene expression over the plasmid DNA-only group. Moreover, 
transgene expression mediated by this method was seen, at least up to 24 weeks. These 
results demonstrate that ultrasound-mediated destruction of microbubbles loaded with 
plasmid-DNA is a feasible and efficient technique for local gene delivery within the 
intervertebral disc. 
2.2 New strategy for intradiscal gene therapy 
Despite much research effort, the successful biological treatment of degenerated discs is still 
limited to the injury induced disc degeneration (stub injury) model using relatively small 
animals. There are considerable limitations arising from the unique anatomy and 
physiology of the disc. 
2.2.1 Limitations of biological approaches for degenerated disc 
The lumbar intervertebral disc is known to be the largest avascular organ in the human 
body and the main path of nutrition or oxygen supply is passive diffusion via the endplates, 
resulting in poor nutrition and low oxygen tension, especially near the center of the disc 
(Grunhagen et al., 2006). Therefore, the metabolism in this area has to be relatively 
anaerobic, leading to the production of lactate, which in turn produces low pH inside of the 
disc (Nachemson, 1969). Low nutrition and oxygen tension, low pH, and high positive 
pressure make the interior of the intervertebral disc a harsh biological environment. 
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Therefore, NP cells existing in this environment must be highly differentiated to survive, 
which results in relative stability in terms of cell proliferation. Moreover, probably due to 
the low nutrition supply, the NP has a very low cell number compared with the rich extra-
cellular matrix and a significantly low cellular metabolism.  
Up to now, the main focus of intradiscal gene therapy and growth factor injection or cell 
therapy approaches has been to stimulate matrix synthesis. However, when taking the disc 
environment into consideration, methods requiring more resources or energy to up-regulate 
or stimulate matrix synthesis as well as cell proliferation seem less likely to result in 
successful disc regeneration. For successful biological treatment, taking into consideration of 
the characteristics of the target organ/tissue, and careful selection of the treatment strategy 
is necessary. As such, a different approach requiring less energy or fewer resources may 
have a better chance of promoting disc regeneration.  
One of these approaches is the down-regulation of gene expressions that are potentially 
harmful for the physiological condition of the disc, and thus may induce degenerative 
change in the disc. This kind of approach focuses more on prophylactic treatment of disc 
degeneration. However, theoretically, it could become a regenerative treatment over an 
extended period (Figure 3). RNA interference (RNAi) is known to be a powerful means of 
sequence-specific gene silencing and would thus be a good candidate for this new strategy. 
 
 
Fig. 3. Theoretical effect of continuous down regulation of catabolism by RNAi. 
2.1.2 Potential application of RNA interference for treatment degenerated disc 
associated disorders  
RNAi was first reported in 1998 by Fire et al. who demonstrated that double-stranded RNA 
induced sequence-specific silencing of gene expression in nematode cells (Fire et al., 1998). 
Elbashir et al. demonstrated that RNAi can be achieved in mammalian cells using 
oligoribonucleotide duplex 21 or 22 bases in length (small interfering RNA; siRNA) 
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(Elbashir et al., 2001). Since then, a numbers of RNAi applications for a variety of 
organs/diseases have been intensively investigated.  
In 2006, Kakutani and Nishida et al. reported for the first time that RNAi targeting 
exogenous reporter gene is effective in silencing transgene expression in nucleus pulposus 
cells in humans and rats in vitro. In their study, two reporter luciferase plasmids (Firefly and 
Renilla) were used. These plasmids were co-transfected with siRNA targeting Firefly 
luciferase to the nucleus pulposus cells extracted from rats and scoliosis patients. The 
inhibitory effects were evaluated by dual luciferase assay for 3 weeks. The results showed 
the expression of Firefly Luciferase was drastically inhibited both in rats (94.7%) and in 
humans (93.7%). These inhibitory effects continued for 3 weeks. The study thus 
demonstrated that siRNA-mediated gene silencing in rat and human disc cells in vitro is 
feasible and effective in down regulating specific gene expression. 
In their follow-up study, Suzuki and Nishida et al. reported the effectiveness of the DNA 
vector-based RNAi technique in vitro for a prolonged RNAi effect. Furthermore, they 
demonstrated the simple unmodified siRNA-mediated RNAi effect in intervertebral discs in 
vivo (rat coccygeal discs) resulted in a prolonged period of up to 24 weeks (168 days). 
Additionally, this study demonstrated long-term down-regulation is possible not only for 
the exogenous reporter gene, but also for the endogenous gene (Fas ligand) expression in rat 
discs in vivo. As a result of the prolonged silencing effect after a single intradiscal 
transduction of unmodified siRNA, this gene delivery method is suitable as a local therapy 
for disc degeneration and associated disorders by down-regulating some harmful genes for 
the normal physiology of the disc, which may cause disc degeneration. (Figure 4) 
 
 
Fig. 4. Long-term RNAi effect mediated by unmodified siRNA in the nucleus pulposus in 
vivo (Modified from Suzuki et al., 2009). 
More recently, Sudo and Minami reported successful RNAi in the degenerative process of 
the disc by down regulating Apotosis related factor caspase 3 (Sudo & Minami, 2011). In 
their report, they investigated the effects of siRNA targeting caspase 3 on rabbit nucleus 
pulposus (NP) cells in vitro. The researchers concluded that these findings indicated caspase 
3 knockdown in intervertebral disc cells is effective in preventing apoptotic cell death, and 
thus could regulate intervertebral disc degeneration. 
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3. Conclusion 
The gene therapy approach for the degenerated disc initially used a viral vector to transfer 
genes to stimulate important matrix synthesis for the disc such as proteoglycan. However, 
due to problems associated with a virus vector, a non-virus mediated gene transfer 
technique has been explored while the  development of more sophisticated virus vectors 
remain a subject of investigation. 
The difficulties of disc regeneration using a biological approach originate from the unique 
anatomical and physiological character of the disc. However, if we disregard these specific 
properties and the associated limitations of the disc, there may be little chance for successful 
regeneration. The successful treatment strategy for osteoporosis patients suggests us that the 
down-regulation of catabolic factors may be a more suitable strategy especially for 
organs/tissues with low cell metabolism and extensive extra-cellular matrix including bone 
or interverteral disc. As such, RNAi has been applied to the disc to down-regulate catabolic 
factors in the disc and correct imbalance between anabolic and catabolic factors with 
minimal nutrition requirements. This kind of approach would focus more on prophylactic 
treatment of disc degeneration. However, the potential exists for it to become a regenerative 
treatment over an extended period.  
There are many issues to be overcome before the clinical use of RNAi can be permitted in 
patients suffering from degenerated discs and associated diseases. However, the 
demonstration that siRNA transfected by a nonvirus-mediated method can effectively 
inhibit specific gene expression in nucleus pulposus cells in vivo for an extended period lead 
the way for the exploration of siRNA as a novel strategy in gene therapy for the treatment of 
disc degeneration and associated diseases. 
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